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Abstract
Background: Although chemotherapy is not a routine recommendation for stage II colon cancer by the U.S. national 
guidelines, 20-30% of patients have received chemotherapy. This study investigated whether screening 
mammography use before the cancer diagnosis was associated with chemotherapy use among female elderly patients 
with stage II colon cancer.
Methods: Retrospective cohort study on 2910 female stage II colon cancer patients aged 67-79 using the Surveillance, 
Epidemiology and End Results (SEER)-Medicare data (1996-2002). Screening mammography use and chemotherapy 
use were identified using Medicare claims data. Multivariate logistic regression and Kaplan-Meier curves were used.
Results: About 25% of female elderly patients received chemotherapy. The chemotherapy rates increased from 22% in 
1996-1998 to 26% in 2001-2002. After adjusting for socio-demographic variables, tumor characteristics and Charlson 
index for comorbidities, the odds of receiving chemotherapy were 28% higher among those who had a screening 
mammogram before the cancer diagnosis than those who did not (OR: 1.28, 95% CI: 1.07-1.54). Those with a prior 
mammogram also received chemotherapy earlier than those without. In addition, patients with unfavorable tumor 
characteristics were more likely to receive chemotherapy. Mammography use before the cancer diagnosis was 
associated with favorable tumor characteristics.
Conclusions: Despite the controversy about the chemotherapy use among stage II colon cancer, female elderly 
patients still received chemotherapy at a high rate. Our findings suggest that patient's health beliefs and health care 
seeking behavior, together with physician's recommendation, play important roles in the cancer treatment decision.
Background
Each year, about 75,000 people are diagnosed with colon
cancer in the U.S. [1,2]. Among them, 37% have a stage II
cancer diagnosis according to American Joint Committee
o n  C a n c e r  ( A J C C )  s c h e m a ,  i n  w h i c h  c a n c e r  i s  s t i l l
restricted locally and no positive lymph node is detected.
Appropriately treated, the five-year relative survival rate
for these patients is about 80% [1].
The primary treatment for stage II colon cancer is sur-
gery. Radiation therapy is not recommended for treating
stage II colon cancer because of the side effects on other
abdominal organs. Since the 1990s, it has been estab-
lished that adjuvant chemotherapy can significantly
improve survival among patients with stage III cancer
(cancer with positive lymph nodes detected) [3]. How-
ever, the effectiveness and long term benefits of adjuvant
chemotherapy for patients with stage II cancer are still
uncertain. The survival benefit might be only 2-5% [4],
and the complications of chemotherapy such as severe
diarrhea and risk of leucopenia may outweigh the bene-
fits of chemotherapy. Thus, the U.S. national guidelines
do not recommend chemotherapy as a routine treatment
for those with stage II cancer [3]. Nonetheless, about 20-
30% of these patients have received chemotherapy [4].
There are both clinical and non-clinical reasons for
patients with stage II colon cancer to receive chemother-
apy. Patients with certain tumor characteristics such as a
poorly differentiated tumor grade, bowel obstruction or
perforation, or tumor extended through serosa (Stage IIb)
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may have a poor prognosis similar to that of stage III can-
cer [5]. These patients may be more likely to receive che-
motherapy. In addition, when evaluating the risks and
benefits of chemotherapy during the treatment decision
process, physician's and patient's beliefs in the effect of
chemotherapy may play important roles. Some physicians
may be more likely to recommend chemotherapy to
patients, and a physician's recommendation is the most
important determinant for many health care decisions
[6]. Furthermore, as suggested by health belief model [7],
patient's perception of the vulnerability to colon cancer
and its recurrence, the risks and benefits of chemother-
apy, and patient's self-efficacy play important roles in
forming a patient's own decision. Some patients may be
more likely to request chemotherapy or accept the che-
motherapy recommendation.
No clinical research has examined the role of patient's
health beliefs, revealed in health care seeking behaviors
such as screening mammography among women, in the
cancer treatment decision. Screening mammography is a
highly recommended preventive service by the national
guidelines and also well known among women. However,
despite the fact that Medicare covers screening mam-
mography since 1994, elderly women who were disabled,
with low socio-economic status and insufficient health
literacy were less likely to have a screening mammogram
within two years. In addition, previous studies have
shown that preventive services tend to cluster within cer-
tain patients [8]. Regular mammography use has been
associated with not only lower breast cancer staging [9]
but also higher colorectal cancer screening [10]. Thus,
patients with regular mammography use are more health
conscious and in general have better health behavior
[11,12]. The use of screening mammography before the
cancer diagnosis is a good surrogate for a broader health
utilization pattern.
In this study, we used Surveillance, Epidemiology and
End Results (SEER)-Medicare linked data to compare the
chemotherapy use between female stage II colon cancer
patients who had a screening mammogram before the
cancer diagnosis and those who did not. We hypothe-
sized that those who had a screening mammogram before
the cancer diagnosis would also be more likely to receive
adjuvant chemotherapy than those who did not have a
prior mammogram.
Methods
Cohort definition
The 2006 SEER-Medicare linked data were used in this
study. The details of SEER-Medicare data can be found at
the National Cancer Institute SEER website [13]. Briefly,
as of 2002, SEER included all cancer patients residing in
17 geographic areas, covering about 26% of total US pop-
ulations. For cancer patients 65 years of age and older,
97% of them were linked to Medicare claims data [14].
We identified all incident female colon cancer patients
from 1996 to 2002 using the first primary cancer site code
(15-23, colon cancer) (n = 49,086) in the SEER Patient
Entitlement and Diagnosis Summary File (PEDSF). We
excluded patients who had a second malignancy, includ-
ing colon cancer, within the first year, and included only
those with stage II cancer (n = 13,609). Since identifying
screening mammography use prior to the cancer diagno-
sis requires two years of Medicare claims, and mammog-
raphy rate is significantly lower among people 80 years
and older [15], we restricted patients to those with 67 to
79 years of age at the time of cancer diagnosis (n = 5,912).
In addition, previous studies have also shown colon can-
cer patients 80 years and older also have significantly
lower chemotherapy rates than younger patients [16].
Similar to other studies using SEER-Medicare data, we
hierarchically excluded the cancer patients who did not
have both Medicare Part A (hospital insurance) and Part
B (medical insurance for office visit) enrollment (Both
Part A and B were administered by the US Center for
Medicare and Medicaid Service, i.e., CMS) (n = 428),
were enrolled in managed care (commercial insurance
and health care groups contracted with CMS to manage
Medicare beneficiaries) (n = 1,810), or had end-stage
renal disease (n = 46) during two years before and one
year after the cancer diagnosis. We also excluded those
who died (n = 247) or were admitted to hospice (n = 17)
within six months around the cancer diagnosis because
the treatment decisions for these patients were likely dif-
ferent from others. The date of death was based on Medi-
care entitlement information included in PEDSF. In-
hospital surgical treatment for colon cancer was searched
using the International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM) procedure
codes 45.7x, 45.8, 48.4x, 48.5, and 48.6x, in the Medicare
Provider Analysis and Review (MedP AR) claims within
six months around the cancer diagnosis. Those who did
not have a colon cancer related surgery or a surgeon's
claim in the Medicare National Claim History (NCH)
Carrier during that time window were also excluded (n =
199). Teaching hospital was defined as any hospital with a
non-zero indirect cost for medical education in the Med-
PAR hospitalization claims for the colon surgery.
The study has been approved by the Institutional
Review Board (IRB) at the University of Minnesota where
the study was initially conducted. The data used in this
study were obtained from National Cancer Institute
through IMS under the SEER-Medicare data user agree-
ment.
Adjuvant chemotherapy use
The use of adjuvant chemotherapy treatment was identi-
fied from Medicare NCH Carrier claims (The NCH fileYu and McBean BMC Health Services Research 2010, 10:98
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contain claims for services provided by physicians and
stand-alone clinics), Durable Medical Device and Outpa-
tient file claims were searched using Healthcare Common
Procedure Coding System (HCPCS) level II codes for
commonly used chemotherapy drugs [14]. 99.3% patients
who had chemotherapy received 5-fluorouracil (5-FU,
J9190) or capecitabine (J8520, J8521), both of which are
used either alone, or with leucovorin (J0640), floxuridine
(J9200), or oxaliplatin (J9263), irinotecan (J9206). The
waiting period for the chemotherapy initiation was
defined as the time window from the date of cancer sur-
gery to the date of the first claim containing chemother-
apy drugs [17]. Adjuvant chemotherapy is usually started
within three months of surgery [16,18]. In our study, 4.2%
of patients started chemotherapy after six months. They
were excluded (n = 134) because the purpose for the che-
motherapy was uncertain [17].
The duration of chemotherapy was defined as the time
window from the first to the last claim that contained
chemotherapy drug information. Since 1995, typical che-
motherapy usually lasts for about six months [3]. We
excluded those who were on chemotherapy for more than
one year (4.0%, n = 121) because these patients might
have a recurrence or the intention of treatment might be
a long treatment regimen [19].
Screening mammography use before the cancer diagnosis
Screening mammography within the two years before the
cancer diagnosis was identified using HCPCS codes
76092, G0202, and G0203, and ICD-9-CM code V76.12,
in the Medicare NCH Carrier and Outpatient files
[15,20].
Tumor characteristics
Certain tumor characteristics have been related to poor
prognosis and may affect chemotherapy decision among
stage II colon cancer [5]. We distinguished tumors based
on the detailed staging information using SEER extent of
diseases codes (defined in SEER EOD-88 3rd edition
(1998): 40: invasion through muscularis; 45: extension to
adjacent tissue; 50: invasion of/through serosa), and iden-
tified bowel obstruction (ICD-9 diagnosis code: 560.89
and 560.90) and bowel perforation (ICD-9 diagnosis
codes: 569.83) in the MedPAR claims within four months
of the cancer surgery. Those with tumors that have
invaded of/through serosa or having bowel obstruction or
perforation were Stage IIb colon cancer. Tumor grade
from SEER PEDSF was regrouped as well/moderately dif-
ferentiated and poorly differentiated/other. The "other"
group includes unknown grade or ungraded (3.3%, n =
95). They were combined with the poorly differentiated
group based on the principle of conservative analysis. In
addition, since the number of lymph node examined dur-
ing the surgery has been related to the quality of surgery
and cancer survival, it was grouped as less than 12, and 12
or more [21].
Visit to oncologists
Chemotherapy is mainly administered by oncologists. In
this study, we used all chemotherapy claims from 1996 to
2002 for breast cancer, colorectal cancer, and uterine can-
cer to identify all physicians who were likely to administer
chemotherapy to Medicare cancer patients. Including all
these cancer types allows us to have a larger and more
complete Medicare claim history to search for possible
oncologists and capture those who only saw a small num-
ber of elderly patients. An oncologist was defined as a
physician who had 5 or more chemotherapy administra-
tion or drug claims per year and had seen 2 or more of
cancer patients during the study period. Physicians with
the HCFA specialty codes (90: medical oncology, 82/83:
hematology/oncology, 91: surgical oncology and 70: mul-
tiple specialty, 11: internal medicine) accounted for more
than 95% of total oncologists identified.
Patient socio-demographic variables and comorbidities
Patient socio-demographic variables included age group
(67-69, 70-74, and 75-79), race/ethnicity (black, white,
and other), state buy-in status (state buy-in means the
state pays part or all of the patient's Medicare Part B pre-
mium or the person is in the Medicaid program), median
household income at the census tract based on the 2000
census (If the value was missing, it was imputed from the
corresponding zip code median household income), met-
ropolitan residence status (yes versus no), and marital
status at the time of cancer diagnosis (married/living with
a partner versus living alone). They were obtained from
SEER PEDSF.
Patient comorbidities were assessed using Charlson
score [22] which was calculated from ICD-9 diagnosis
codes in the Medicare NCH, MedPAR and Outpatient
claims, in the two years before the month of cancer diag-
nosis using Deyo and Klabunde modified algorithm
[23,24]. The Charlson score was grouped as zero, 1, 2, and
3+. Cancer diagnosis was excluded in calculating the
above score.
Statistical analysis
Descriptive statistics were calculated for patient socio-
demographic variables, comorbidities, tumor characteris-
tics, and oncologist visit, stratified by mammography use
before the cancer diagnosis. Statistical significance was
assessed using t-test for continuous variables and chi-
square test for categorical variables. Multivariate adjusted
chemotherapy rates were computed as 1/(1+exp(-bx))
from the logistic regression with chemotherapy use (yes/
no) as the dependent variable. The time from the cancer
surgery to the first chemotherapy use was presented
using Kaplan Meier survival curves stratified by priorYu and McBean BMC Health Services Research 2010, 10:98
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mammography use. Curves were inverted and also trun-
cated at 160 days to be more interpretable. Odds ratios
for the determinants of chemotherapy use were obtained
from the above multivariate logistic regression in which
all determinants were mutually adjusted. To take account
of possible clustering effect of patients, we adopted the
Generalized Estimate Equations (GEE) method in the
multivariate logistic regression with the hospital where
patient received the surgery as the cluster variable. All the
statistical analyses were performed using SAS 9.1.4 (Proc
GLM, GENMOD, and LIFETEST) (SAS Institute, Cary,
NC).
Results
Our study included 2910 female patients with stage II
colon cancer. Their characteristics are shown in Table 1,
stratified by screening mammography use status before
the cancer diagnosis. Compared with those who did not
have a prior mammogram, those who had a prior mam-
mogram were more likely to be younger , white, live in
higher income areas, married, healthier, have the colon
surgery done in teaching hospitals, and visit an oncologist
after the surgery. Further, those who had a prior mammo-
gram had favorable tumor characteristics, were more
likely to have 12 or more lymph nodes examined, and
were less likely to have bowel obstruction or perforation.
Among patients with stage II colon cancer, 25.2%
received chemotherapy after the cancer surgery. The
crude chemotherapy rates by the mammography use
before the cancer diagnosis were presented in Table 2.
Those who had a prior mammogram were more likely to
receive chemotherapy than those who did not (28.2% ver-
sus 22.2%, P < 0.001). Furthermore, younger age, urban
residence, better health status, and unfavorable tumor
characteristics were related to higher chemotherapy use
(Table 2). The time from the cancer surgery to the first
chemotherapy use is shown in Figure 1. The chemother-
apy was initiated earlier among those who had a prior
screening mammogram than those who did not (the
median time to the chemotherapy: 52.4 vs. 56.5 days, p =
0.015) (Figure 1). Those who had a prior mammogram
also had a higher chemotherapy rate by the fifth month
than those who did not (age adjusted chemotherapy rate:
27.4% vs. 21.9%, p = 0.0006).
After adjusting for patient socioeconomic variables,
comorbidities, tumor characteristics, and oncologist visit,
the odds of receiving chemotherapy was 28% higher
among those who had a prior mammogram than those
who did not (Odds ratio: 1.28, 95% Confidence Interval
(CI): 1.07-1.54) (Table 3). As expected, the strongest
determinant was whether the patient visited an oncolo-
gist after the surgery. Furthermore, patients 75-79 years
of age were significantly less likely to receive chemother-
apy than the youngest patients (67-69 years of age), while
there was no racial difference in the adjusted chemother-
apy rates. In addition, the adjusted chemotherapy rates
were higher among those who did not have state subsidy
for Medicare premium, were married, lived in metropoli-
tan areas and had unfavorable tumor characteristics. Par-
ticularly, the adjusted chemotherapy rate was 39.3% for
those with bowel obstruction or perforation, and 23.4%
for those without (OR: 2.22, 95%CI: (1.55-3.16)). For
those with poorly differentiated tumor grade, the
adjusted chemotherapy rate was 27.2%, compared with
23.7% for those with well/moderately differentiated
tumor grade (p = 0.06). In addition, for those with tumor
that only invaded through muscularis, the adjusted che-
motherapy rate was only 18.7%, while the adjusted rate
was 26.9% and 24.4% for those with tumor that invaded
adjacent tissue or through serosa (p < 0.001). Finally, the
adjusted chemotherapy rate was also significantly higher
in 2001 and 2002 than previous periods (from 21.6% for
1996-1998 to 26.1% for 2001-2002, p for trend = 0.01).
Discussion
In this study the odds of receiving chemotherapy were
28% higher among female stage II colon cancer patients
who had a screening mammogram before the cancer
diagnosis than those who did not have a prior mammo-
gram. They were also more likely to receive the chemo-
therapy earlier. In addition, mammography use before the
cancer diagnosis was associated with favorable tumor
characteristics. Since chemotherapy after the surgery was
almost always administered by oncologists, we found that
visiting an oncologist after the cancer surgery was the
most important determinant of receiving chemotherapy.
We repeated all the analyses among those with an oncolo-
gist visit and found that our conclusions on the determi-
nants of chemotherapy were not changed (Data not
shown).
Recent studies, including both randomized clinical tri-
als [25] and observational studies [4,5], failed to demon-
strate a clear benefit of chemotherapy for stage II colon
cancer. However, we found that the chemotherapy rate
among female patients with stage II colon cancer was
about 25%, and the rate increased significantly from 1996
to 2002. The chemotherapy rate was highest in youngest
patients (age 67-69), suggesting the chemotherapy rate
might be even higher among patients younger than age
67.
In addition, because certain factors such as poor tumor
characteristics, bowel obstruction and perforation are
related to a poor prognosis similar to that of stage III
colon cancer [18], patients with unfavorable clinical indi-
cations were significantly more likely to receive chemo-
therapy than those without these clinical characteristics.
Our findings are consistent with those of previous studies
[16,17,19]. However, more than 20% of patients withYu and McBean BMC Health Services Research 2010, 10:98
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Table 1: Patient Characteristics by Screening Mammography Use before the Cancer Diagnosis, SEER-Medicare 1996-2002
Mammography before cancer diagnosis
Yes No P 
value
Total
N 1,389 1,521 2,910
Age, in years Mean (SD) 73.8 (3.6) 74.1 (3.6) 0.03 74.0 (3.6)
Age-group 67-69 228 (16.4%) 223 (14.7%) 0.28 451 (15.5%)
70-74 496 (35.7%) 531 (34.9%) 1027 (35.3%)
75-79 665 (47.9%) 767 (50.4%) 1432 (49.2%)
Race/ethnicity White 1224 (88.1%) 1286 (84.6%) 0.02 2510 (86.3%)
Black 95 (6.8%) 133 (8.7%) 228 (7.8%)
Other 70 (5.0%) 102 (6.7%) 172 (5.9%)
State buy-in status Yes 206 (14.8%) 387 (25.4%) <0.001 593 (20.0%)
Married Yes 694 (50.0%) 600 (39.5%) <0.001 1294 (44.5%)
Metropolitan residence Yes 1111 (80.0%) 1259 (82.8%) 0.05 2370 (81.4%)
Census tract median household income <$35,000 551 (39.7%) 669 (44.0%) 0.05 1220 (41.9%)
$35,000-$60,000 503 (34.3%) 496 (32.6%) 999 (34.3%)
>$60,000 335 (23.8%) 356 (23.4%) 691 (23.8%)
Charlson score 0 396 (28.5%) 539 (35.4%) <0.001 935 (32.1%)
1 507 (36.5%) 426 (28.0%) 933 (32.1%)
2 283 (20.4%) 235 (15.5%) 518 (17.8%)
3+ 203 (14.6%) 321 (21.1%) 524 (18.0%)
Teaching hospital 792 (57.9%) 836 (55.0%) 0.26 1628 (56.0%)
Tumor grade Well/moderately differentiated 1051 (75.7%) 1173 (77.1%) 0.36 2224 (76.4%)
Extent of disease 1 invasion through muscularis 644 (46.4%) 638 (42.0%) 0.03 1282 (44.1%)
extension to adjacent tissue 550 (39.6%) 621 (40.8%) 1171 (40.2%)
invasion of/through serosa 79 (5.7%) 95 (6.3%) 174 (6.0%)
Other 116 (8.4%) 167 (11.0%) 283 (9.7%)
Bowel obstruction or perforation 74 (5.3%) 134 (8.8%) <0.001 208 (7.2%)
More than 12 lymph nodes examined 670 (48.2%) 682 (44.8%) 0.07 1352 (46.5%)
Oncologist visit 1078 (77.6%) 1148 (75.5%) 0.18 2226 (76.5%)
Year 1996-1998 341 (24.6%) 528 (34.7%) <0.001 869 (29.9%)
1999-2000 419 (30.2%) 406 (26.7%) 825 (28.4%)
2001-2002 629 (45.3%) 587 (38.6%) 1216 (41.8%)
Note: 1. The extent of disease for colon cancer is defined in SEER EOD-88 3rd edition (1998) 2. The percentages in the parentheses are column 
percentsYu and McBean BMC Health Services Research 2010, 10:98
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Table 2: Unadjusted Chemotherapy Rate among Female Patients with Stage II Colon Cancer, SEER-Medicare 1996-2002
Mammography use before cancer diagnosis
Yes
(N = 1,389)
No
(N = 1,521)
P value Total
Total 392 (28.2%) 338 (22.2%) <0.001 730 (25.1%)
Age-group 67-69 78 (34.2%) 65 (29.2%) <0.001 143 (31.7%)
70-74 163 (32.7%) 155 (29.2%) 318 (31.0%)
75-79 151 (22.7%) 118 (15.4%) 269 (18.8%)
Race/ethnicity White 348 (28.4%) 294 (22.9%) 0.28 642 (25.6%)
Black 24 (25.3%) 24 (18.0%) 48 (21.1%)
Other 20 (28.6%) 10 (19.6%) 40 (23.3%)
State buy-in 
status
No 350 (29.6%) 285 (25.1%) <0.001 635 (27.4%)
Yes 42 (20.4%) 53 (13.7%) 95 (16.0%)
Marriage status Single 169 (24.3%) 164 (17.8%) <0.001 333 (20.6%)
Married 223 (32.1%) 174 (29.0%) 397 (30.7%)
Metropolitan 
residence
No 64 (23.0%) 38 (14.5%) <0.001 102 (18.9%)
Yes 328 (29.5%) 300 (23.8%) 628 (26.5%)
Census tract 
median 
household 
income
<35,000 136 (24.7%) 123 (18.4%) <0.001 259 (21.2%)
35,000-60,000 151 (30.0%) 123 (24.8%) 274 (27.4%)
>60,000 105 (31.3%) 92 (25.8%) 197 (25.1%)
Charlson score 0 114 (28.8%) 137 (25.4%) <0.001 251 (26.8%)
1 156 (30.8%) 109 (25.6%) 265 (28.4%)
2 78 (27.6%) 40 (17.0%) 118 (22.8%)
3+ 44 (21.7%) 52 (16.2%) 96 (18.3%)
Hospital type Non-teaching 171 (28.6%) 139 (20.3%) 0.35 310 (24.2%)
Teaching 221 (27.9%) 199 (23.8%) 420 (25.8%)
Tumor grade Well/moderately 
differentiated
292 (27.8%) 249 (21.2%) 0.10 541 (24.3%)
Poorly 
differentiated/
other
100 (29.6%) 89 (25.6%) 189 (27.6%)Yu and McBean BMC Health Services Research 2010, 10:98
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Extent of diseases invasion through 
muscularis
143 (22.2%) 103 (16.1%) <0.001 246 (19.2%)
extension to 
adjacent tissue
173 (31.5%) 148 (23.8%) 321 (27.4%)
invasion of/
through serosa
22 (27.9%) 21 (22.1%) 43 (24.7%)
Other 54 (46.6%) 66 (39.5%) 120 (42.4%)
Bowel 
obstruction or 
perforation
No 356 (27.1%) 293 (21.1%) <0.001 649 (24.0%)
Yes 36 (48.7%) 45 (33.6%) 81 (38.9%)
More than 12 
lymph nodes 
examined
No 187 (26.0%) 180 (21.5%) 0.05 367 (23.6%)
Yes 205 (30.6%) 158 (23.2%) 363 (26.9%)
Oncologist visit No 20 (6.4%) 15 (4.0%) <0.001 35 (5.1%)
Yes 372 (34.5%) 323 (28.1%) 695 (31.2%)
Year 1996-1998 82 (24.1%) 112 (21.2%) 0.07 194 (22.3%)
1999-2000 125 (29.8%) 88 (21.7%) 213 (25.8%)
2001-2002 185 (29.4%) 138 (23.5%) 323 (26.6%)
Note: The number in each cell is the number of people who received chemotherapy, and the percentage in the parentheses is the 
corresponding unadjusted chemotherapy rate for that cell
Table 2: Unadjusted Chemotherapy Rate among Female Patients with Stage II Colon Cancer, SEER-Medicare 1996-2002 (Continued)
favorable tumor characteristics had also received chemo-
therapy, suggesting that the chemotherapy decision is not
solely based on clinical indications. Characteristics
related to both physicians and patients may play impor-
tant roles in the treatment decision process.
As  s t a t ed  e a r l i e r ,  f o r  m a n y  h ea l t h  s e rvi c es,  t h e  m os t
important factor is physician's recommendation [6].
National guidelines encourage physicians to discuss the
risks and benefits of chemotherapy with patients, and
inform patients that chemotherapy for stage II colon can-
cer is not a routine recommendation [3]. Our study sug-
gests that other factors may be important. The patient's
knowledge, attitudes, and beliefs towards colon cancer
and chemotherapy may play key roles during the treat-
ment decision making process [7]. Further, women who
had regular mammograms were found to be more likely
to have colorectal cancer screening [10]. Therefore,
although regular mammography may reflect health sta-
tus, mobility, and access to care, patients with regular
mammography might be more aggressive in seeking
health care and hold stronger beliefs in maintaining good
health than those who did not have regular mammogra-
phy use [11,12]. Screening mammography before the can-
cer diagnosis could be considered as a good surrogate for
health beliefs regarding cancer care in general. As sug-
gested by the health belief model, those who had screen-
ing mammograms might perceive a higher risk of
recurrence of colon cancer, and/or larger benefits of che-
motherapy than patients without prior screening mam-
mograms. In our study, we found that those with a prior
mammogram were more likely to have fewer comorbidi-
ties and less advanced diseases, and more likely to visit an
oncologist after the surgical treatment. Thus, it could be
expected that they would be more willing to adopt che-
motherapy.
Consistent with other studies, we confirmed that
patient socioeconomic factors are important in cancer
treatment decision [26]. Despite the uncertain benefits of
chemotherapy for stage II colon cancer, patients who had
a state subsidy for their Medicare premium or were in the
Medicaid program had significantly lower rates of che-
motherapy use, suggesting certain barriers to care existed
for these Medicare beneficiaries.
Our study is based on a large and representative popu-
lation. The high accuracy and representativeness of the
SEER cancer registries and comprehensive MedicareYu and McBean BMC Health Services Research 2010, 10:98
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claims provided a useful tool to examine the pattern of
care among cancer patients. Thus, our findings and con-
clusions may be generalized to the entire U.S. elderly
female population. Furthermore, our study has demon-
strated that mammography use before the cancer diagno-
sis can predict patients' behavior in choosing cancer
treatment. We know of no other study that has examined
the link between screening mammography use and can-
cer treatment.
Because this was an observational study based on
Medicare claims data, there are some potential weak-
nesses. We did not have detailed clinical information for
each patient except for the Charlson score which was
based on the diagnosis codes on Medicare claims. Thus,
although we were able to include some tumor character-
istics and other clinical indications from the SEER data,
we were not able to capture the full spectrum of illness
that may have affected the decision to use chemotherapy.
Since the decision of chemotherapy use for each patient is
made individually, we also did not know how physician
and patient communicated about the treatment options.
Further research is needed to elucidate the interaction
between patient and physician during the treatment deci-
sion making process. In addition, we found the chemo-
therapy was initiated about 4 days earlier among those
who had a prior screening mammography than those
who did not. Although this may not be clinically signifi-
cant, it is of importance in the view of health care utiliza-
tion on average, and confirms that those with regular
mammography are more aggressive in seeking health
care. Furthermore, we did not directly measure the health
beliefs because only administrative data were used. We
used screening mammography before the cancer diagno-
sis as a surrogate for health care seeking behavior. Direct
measures of health beliefs and health care seeking behav-
iors would be desirable in future studies. Finally, given the
nature of observational study design, we could not estab-
lish any causal relationship between mammography use
prior to surgery and the receipt of chemotherapy for stage
II colon cancer. Nevertheless, our study provided strong
evidence that patient's health care seeking behavior might
play an important role in the treatment decision process.
Figure 1 Time to the Chemotherapy Use among Female Patients with Stage II Colon Cancer, SEER-Medicare 1996-2002.
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Table 3: Determinants of Chemotherapy Use among Female Patients with Stage II Colon Cancer, SEER-Medicare 1996-
2002
Odds ratio 95% CI
Prior mammography use No Reference
Yes 1.28 (1.07-1.54)
Age-group 67-69 Reference
70-74 1.00 (0.77-1.30)
75-79 0.49 (0.39-0.63)
Race/ethnicity White Reference
Black 0.99 (0.67-1.45)
Other 1.31 (0.84-2.05)
State buy-in status No Reference
Yes 0.56 (0.43-0.73)
Marriage status Single Reference
Married 1.47 (1.20-1.80)
Metropolitan residence No Reference
Yes 1.38 (1.00-1.90)
Census tract median 
household income
<35,000 Reference
35,000-60,000 1.14 (0.92-1.42)
>60,000 0.98 (0.75-1.29)
Charlson score 0 Reference
1 1.11 (0.87-1.42)
2 0.86 (0.65-1.14)
3+ 0.77 (0.56-1.04)
Hospital type Non-teaching Reference
Teaching 1.10 (0.89-1.37)
Tumor grade Well/moderately 
differentiated
reference
Poorly differentiated/other 1.14 (0.93-1.39)
Extent of diseases invasion through muscularis Reference
extension to adjacent tissue 1.48 (1.20-1.83)
invasion of/through serosa 1.27 (0.86-1.89)
Other 2.91 (2.18-3.90)Yu and McBean BMC Health Services Research 2010, 10:98
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Bowel obstruction or 
perforation
No Reference
Yes 2.22 (1.55-3.16)
More than 12 lymph nodes 
examined
No Reference
Yes 1.09 (0.91-1.31)
Oncologist visit No Reference
Yes 8.37 (5.78-12.1)
Year 1996-1998 Reference
1999-2000 1.28 (0.98-1.66)
2001-2002 1.36 (1.06-1.73)
Note: The logistic model was mutually adjusted for all these determinants.
Table 3: Determinants of Chemotherapy Use among Female Patients with Stage II Colon Cancer, SEER-Medicare 1996-
2002 (Continued)
Conclusion
Elderly women with stage II colon cancer had a high rate
of chemotherapy despite the controversy around its use.
Those who had a screening mammogram in the two years
before the cancer diagnosis were more likely to receive
chemotherapy than those who did not have a prior mam-
mogram, suggesting that the patients' knowledge, atti-
tudes and beliefs towards cancer and its treatment, and
general health care seeking behaviors is very important in
the cancer treatment decision. Physicians need to com-
municate with patients more effectively so that the deci-
sion to adopt chemotherapy is made appropriately based
on the national guidelines.
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